- Home
- MNTS vs ICU Comparison
MNTS vs ICU Comparison
Compare MNTS & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNTS
- ICU
- Stock Information
- Founded
- MNTS 2017
- ICU 2018
- Country
- MNTS United States
- ICU United States
- Employees
- MNTS N/A
- ICU N/A
- Industry
- MNTS Military/Government/Technical
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- MNTS Industrials
- ICU Health Care
- Exchange
- MNTS Nasdaq
- ICU Nasdaq
- Market Cap
- MNTS 8.1M
- ICU 9.5M
- IPO Year
- MNTS N/A
- ICU N/A
- Fundamental
- Price
- MNTS $1.15
- ICU $0.66
- Analyst Decision
- MNTS
- ICU
- Analyst Count
- MNTS 0
- ICU 0
- Target Price
- MNTS N/A
- ICU N/A
- AVG Volume (30 Days)
- MNTS 401.1K
- ICU 5.7M
- Earning Date
- MNTS 05-15-2025
- ICU 08-12-2025
- Dividend Yield
- MNTS N/A
- ICU N/A
- EPS Growth
- MNTS N/A
- ICU N/A
- EPS
- MNTS N/A
- ICU N/A
- Revenue
- MNTS $1,923,000.00
- ICU $428,000.00
- Revenue This Year
- MNTS $286.00
- ICU $754.07
- Revenue Next Year
- MNTS N/A
- ICU $100.09
- P/E Ratio
- MNTS N/A
- ICU N/A
- Revenue Growth
- MNTS N/A
- ICU N/A
- 52 Week Low
- MNTS $1.03
- ICU $0.31
- 52 Week High
- MNTS $28.56
- ICU $9.09
- Technical
- Relative Strength Index (RSI)
- MNTS 36.86
- ICU 45.72
- Support Level
- MNTS $1.10
- ICU $0.53
- Resistance Level
- MNTS $1.20
- ICU $0.94
- Average True Range (ATR)
- MNTS 0.06
- ICU 0.10
- MACD
- MNTS 0.01
- ICU 0.01
- Stochastic Oscillator
- MNTS 25.58
- ICU 30.91
About MNTS Momentus Inc.
Momentus Inc offers in-space infrastructure services by building transfer and service vehicles that carry satellites and hosted payloads between orbits in space. It is a provider of three critical functions, in the new space economy: Space Transportation, Satellite as a Service, and In-Orbit Servicing.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.